Kim Forest Enterprise Valuation
Is 6645 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6645 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6645 (NT$27.85) is trading above our estimate of fair value (NT$1.25)
Significantly Below Fair Value: 6645 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6645?
Key metric: As 6645 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 6645's PS Ratio? | |
|---|---|
| PS Ratio | 3.2x |
| Sales | NT$472.82m |
| Market Cap | NT$1.53b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.9x |
| Enterprise Value/EBITDA | -13.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6645's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16.1x | ||
6539 DV Biomed | 0.9x | n/a | NT$1.4b |
4131 NeoCore Technology | 17.9x | n/a | NT$1.2b |
6564 Enimmune | 40.9x | n/a | NT$2.1b |
3164 GenMont Biotech Incorporation | 4.7x | n/a | NT$1.7b |
6645 Kim Forest Enterprise | 3.2x | n/a | NT$1.5b |
Price-To-Sales vs Peers: 6645 is good value based on its Price-To-Sales Ratio (3.2x) compared to the peer average (16.1x).
Price to Sales Ratio vs Industry
How does 6645's PS Ratio compare vs other companies in the TW Biotechs Industry?
| 12 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 20.9x | 28.6% | |
6645 Kim Forest Enterprise | 3.2x | n/a | US$46.98m |
3176 Medigen Biotechnology | 3.4x | n/a | US$147.42m |
4169 TCM Biotech International | 4.2x | n/a | US$108.31m |
| 12 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 20.9x | 49.5% | |
6645 Kim Forest Enterprise | 3.2x | n/a | US$46.98m |
Price-To-Sales vs Industry: 6645 is good value based on its Price-To-Sales Ratio (3.2x) compared to the TW Biotechs industry average (20.9x).
Price to Sales Ratio vs Fair Ratio
What is 6645's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6645's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
RBC Bioscience
NT$254.3m
Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.
6848
NT$19.60
7D
-0.5%
1Y
29.8%
YungShin Global Holding
NT$15.4b
Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.
3705
NT$57.90
7D
8.2%
1Y
27.1%
Cenra
NT$6.0b
Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.
1701
NT$21.15
7D
0%
1Y
-8.8%